This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
FluMist - Frozen Formulation
Drug Names(s): influenza virus vaccine live - intranasal
Description: FluMist is an influenza vaccine against influenza A and B viruses administered as an intranasal spray. The original formulation was frozen. AstraZeneca switched to a new, refrigerated formulation for the 2007/2008 flu season.
Deal Structure: In January 1999, the Company signed a worldwide collaborative agreement with Wyeth Lederle Vaccines, a subsidiary of Wyeth, for the development, manufacture, distribution, marketing, promotion, and sale of live, attenuated, cold adapted, nasally delivered influenza vaccines (flu vaccines). Under this agreement, Wyeth has exclusive worldwide rights to market the flu vaccines, excluding Korea, Australia, New Zealand and some South Pacific countries. The two companies will co-promote the flu vaccines in the United States. Wyeth holds the marketing rights for an initial term of seven years from the first commercial sale of the flu vaccines in the U.S. and an initial term of eight years from the first commercial sale of the flu vaccines outside the United States. Wyeth also has an option to extend its rights in the U.S. for an additional four years and to extend its international rights for an additional three years. Extending both U.S. and international rights triggers payments to the...See full deal structure in Biomedtracker
Partners: Pfizer Inc. Becton, Dickinson and Company
FluMist - Frozen Formulation News
Pink Sheet MedImmune refrigerated FluMist clears FDA
Pink Sheet FDA Performance Tracker: User Fee Goal Dates
Pink Sheet MedImmune next-generation FluMist
Additional information available to subscribers only: